Gene therapy from the perspective of systems biology

Feilim Mac Gabhann, Brian H. Annex, Aleksander S Popel

Research output: Contribution to journalArticle

Abstract

Gene therapy research has expanded from its original concept of replacing absent or defective DNA with functional DNA to include the manipulation (increase or decrease) of gene expression by the delivery of modified genes, siRNA or other genetic material via multiple vectors, including naked plasmid DNA, viruses and even cells. Specific tissues or cell types are targeted in order to decrease the risks of systemic or side effects. As with the development of any drug, there is an amount of empiricism in the choice of gene target, route of administration, dosing and, in particular, the scaling-up from preclinical models to clinical trials. High-throughput experimental and computational systems biology studies that account for the complexities of host-disease-therapy interactions hold significant promise in assisting in the development and optimization of gene therapies, including personalized therapies and the identification of biomarkers to evaluate the success of such strategies. This review describes some of the obstacles and successes in gene therapy, using the specific example of growth factor gene delivery to promote angiogenesis and blood vessel remodeling in ischemic diseases; anti-angiogenic gene therapy in cancer is also discussed. In addition, the opportunities for systems biology and in silico modeling to improve on current outcomes are highlighted.

Original languageEnglish (US)
Pages (from-to)570-577
Number of pages8
JournalCurrent Opinion in Molecular Therapeutics
Volume12
Issue number5
StatePublished - Oct 2010

Fingerprint

Systems Biology
Genetic Therapy
Genes
Empiricism
DNA Viruses
DNA
Computational Biology
Computer Simulation
Small Interfering RNA
Blood Vessels
Intercellular Signaling Peptides and Proteins
Plasmids
Biomarkers
Clinical Trials
Gene Expression
Therapeutics
Research
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery
  • Pharmacology

Cite this

Gene therapy from the perspective of systems biology. / Gabhann, Feilim Mac; Annex, Brian H.; Popel, Aleksander S.

In: Current Opinion in Molecular Therapeutics, Vol. 12, No. 5, 10.2010, p. 570-577.

Research output: Contribution to journalArticle

Gabhann, Feilim Mac ; Annex, Brian H. ; Popel, Aleksander S. / Gene therapy from the perspective of systems biology. In: Current Opinion in Molecular Therapeutics. 2010 ; Vol. 12, No. 5. pp. 570-577.
@article{a719eec65b844d01849811339e83e0ee,
title = "Gene therapy from the perspective of systems biology",
abstract = "Gene therapy research has expanded from its original concept of replacing absent or defective DNA with functional DNA to include the manipulation (increase or decrease) of gene expression by the delivery of modified genes, siRNA or other genetic material via multiple vectors, including naked plasmid DNA, viruses and even cells. Specific tissues or cell types are targeted in order to decrease the risks of systemic or side effects. As with the development of any drug, there is an amount of empiricism in the choice of gene target, route of administration, dosing and, in particular, the scaling-up from preclinical models to clinical trials. High-throughput experimental and computational systems biology studies that account for the complexities of host-disease-therapy interactions hold significant promise in assisting in the development and optimization of gene therapies, including personalized therapies and the identification of biomarkers to evaluate the success of such strategies. This review describes some of the obstacles and successes in gene therapy, using the specific example of growth factor gene delivery to promote angiogenesis and blood vessel remodeling in ischemic diseases; anti-angiogenic gene therapy in cancer is also discussed. In addition, the opportunities for systems biology and in silico modeling to improve on current outcomes are highlighted.",
author = "Gabhann, {Feilim Mac} and Annex, {Brian H.} and Popel, {Aleksander S}",
year = "2010",
month = "10",
language = "English (US)",
volume = "12",
pages = "570--577",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Gene therapy from the perspective of systems biology

AU - Gabhann, Feilim Mac

AU - Annex, Brian H.

AU - Popel, Aleksander S

PY - 2010/10

Y1 - 2010/10

N2 - Gene therapy research has expanded from its original concept of replacing absent or defective DNA with functional DNA to include the manipulation (increase or decrease) of gene expression by the delivery of modified genes, siRNA or other genetic material via multiple vectors, including naked plasmid DNA, viruses and even cells. Specific tissues or cell types are targeted in order to decrease the risks of systemic or side effects. As with the development of any drug, there is an amount of empiricism in the choice of gene target, route of administration, dosing and, in particular, the scaling-up from preclinical models to clinical trials. High-throughput experimental and computational systems biology studies that account for the complexities of host-disease-therapy interactions hold significant promise in assisting in the development and optimization of gene therapies, including personalized therapies and the identification of biomarkers to evaluate the success of such strategies. This review describes some of the obstacles and successes in gene therapy, using the specific example of growth factor gene delivery to promote angiogenesis and blood vessel remodeling in ischemic diseases; anti-angiogenic gene therapy in cancer is also discussed. In addition, the opportunities for systems biology and in silico modeling to improve on current outcomes are highlighted.

AB - Gene therapy research has expanded from its original concept of replacing absent or defective DNA with functional DNA to include the manipulation (increase or decrease) of gene expression by the delivery of modified genes, siRNA or other genetic material via multiple vectors, including naked plasmid DNA, viruses and even cells. Specific tissues or cell types are targeted in order to decrease the risks of systemic or side effects. As with the development of any drug, there is an amount of empiricism in the choice of gene target, route of administration, dosing and, in particular, the scaling-up from preclinical models to clinical trials. High-throughput experimental and computational systems biology studies that account for the complexities of host-disease-therapy interactions hold significant promise in assisting in the development and optimization of gene therapies, including personalized therapies and the identification of biomarkers to evaluate the success of such strategies. This review describes some of the obstacles and successes in gene therapy, using the specific example of growth factor gene delivery to promote angiogenesis and blood vessel remodeling in ischemic diseases; anti-angiogenic gene therapy in cancer is also discussed. In addition, the opportunities for systems biology and in silico modeling to improve on current outcomes are highlighted.

UR - http://www.scopus.com/inward/record.url?scp=77957734075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957734075&partnerID=8YFLogxK

M3 - Article

C2 - 20886389

AN - SCOPUS:77957734075

VL - 12

SP - 570

EP - 577

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 5

ER -